Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes have?
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes has 67 citations in the OpenAlex counts ScholarIQ stores.
When was Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes published?
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes has 2020 year in the ScholarIQ index.
What is the open-access status of Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes?
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes has hybrid oa status in the ScholarIQ index.
What is the DOI of Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes?
The DOI for Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes is on the source record.
What is the PMID of Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes?
The PMID for Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes is on the source record.
What is the OpenAlex record for Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes?
The OpenAlex for Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes is on the source record.